WCM 2017 Highlights: Biomarker immunotherapy

November 1, 2017

  • Share this post:

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma.

This highlight consists of the following parts:

  • Michele Teng, PhD – research scientist, QIMR Berghofer Medical Research Institute, Brisbane, Australia: Why does immunotherapy works so well for melanoma?
  • Prof. Levesque Mitchell, MD – dermatologist, University of Zurich Hospital, Zürich, Switzerland: High dimensional single-cell analysis identifies classical monocyte frequencies to be predictive of PFS to anti-PD-1 immunotherapy
  • Prof. Nikolas Haass, MD – dermatologist, University of Queensland, Brisbane, Australia: Tumor heterogeneity, plasticity and drug resistance

The interviews are editorially independent and are financially supported by BMS, Incyte, MSD and Novartis.

Related articles